ESAT6-CFP10

BIOLOGICAL2 trials

Sponsors

Shanghai Public Health Clinical Center, Anhui Zhifei Longcom Biologic Pharmacy Co., Ltd.

Conditions

HealthyLatent tuberculosis infection

Phase 1

Phase I Clinical Human Tolerability Study of Recombinant Mycobacterium Tuberculosis Allergen ESAT6-CFP10

CompletedNCT01999231

Anhui Zhifei Longcom Biologic Pharmacy Co., Ltd.Healthy

Start: 2013-09-30End: 2013-12-31Updated: 2015-03-31

Phase 4

A real-world study of recombinant tuberculosis protein antigen ESAT6-CFP10 for screening for tuberculosis infection in high-risk populations

Active, not recruitingChiCTR2000036369

Shanghai Public Health Clinical CenterLatent tuberculosis infection

Start: 2020-10-01Updated: 2020-09-07

Related Papers

Utility of recombinant fusion protein ESAT6-CFP10 skin test for differential diagnosis of active tuberculosis: A prospective study

Frontiers in Immunology2023-04-256 citations

Safety of Recombinant Fusion Protein ESAT6-CFP10 as a Skin Test Reagent for Tuberculosis Diagnosis: an Open-Label, Randomized, Single-Center Phase I Clinical Trial

Clinical and Vaccine Immunology2016-07-1423 citations